Big Four & Leading Accounting and Consulting Firms – news, opinion and career opportunities for aspiring & current professionals & alumni

Deloitte: Global life sciences outlook

By Rob Starr, Content Manager,

In an effort to deliver better patient outcomes while at the same time counter slow market growth and declining profitability, the global healthcare industry has adopted a new business model that shifts its focus from developing blockbuster drugs and building pipelines to business portfolio evolution, the regulatory landscape and emerging markets and treatment changes outcomes, according to a new report by Deloitte Touche Tohmatsu Limited (DTTL).

The report, 2013 global life sciences outlook: Optimism tempered by reality in a “new normal”, also closely examines the current state of the global life sciences industry and the top issues facing stakeholders. It provides a snapshot of activity in a number of geographic markets such as health care reforms, cost controls, government industry incentives and economic impacts on the industry, along with considerations companies may adopt to grow revenue and market share in 2013 and beyond.

John Rhodes, Life Sciences Sector Leader, DTTL comments:

“To grow in this challenging climate, the global life sciences industry is transitioning away from a primary-care, small-molecule-driven sales model towards targeting specialist secondary care indications through the use of high-value biologic therapies in the developed markets, while also taking a global perspective by marketing branded and off-patent medicines in the fast-growing emerging markets,” he says.


Share this post:

Comments are closed.